Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

7.160 +0.250 (+3.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Expert Ratings for Sage Therapeutics
Via Benzinga
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics's Return On Capital Employed Insights
Via Benzinga
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate
Via Benzinga
Sage Therapeutics: Q2 Earnings Insights
  Sage Therapeutics (NASDAQ:SAGE) reported its Q2 earnings results on Tuesday, August 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Retirement
Exposures Pension Product Safety
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Where Sage Therapeutics Stands With Analysts
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
From Sage Therapeutics
Via Business Wire
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
From Sage Therapeutics, Inc.
Via Business Wire
Mental Health Claims up 75% Since 2019
Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75% from 2019 as more Canadians tapped into their mental health benefits. According to the Canadian... 
Via PressReach
Mental Health Claims up 75% Since 2019
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 23, 2022 – Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75%... 
Via FinancialNewsMedia
Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91. 
Via Investor's Business Daily
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
Today's depression drugs don't fit many patients' needs. Biotech companies may change that. 
Via Investor's Business Daily
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at Upcoming August Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion. 
Via Benzinga
Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
From Sage Therapeutics, Inc.
Via Business Wire
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... 
Via FinancialNewsMedia
Sage Therapeutics to Present at Upcoming June Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same
Sage and Biogen say their MDD drug met every goal in a study of postpartum women. 
Via Investor's Business Daily
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
From Sage Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.